

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN PHARMACEUTICALS INC.,
Petitioner

v.

BOEHRINGER INGELHEIM INTERNATIONAL GMBH,
Patent Owner.

U.S. Patent No. 9,173,859 to Dugi *et al.*
Issue Date: Nov. 3, 2015
Title: Uses of DPP-IV Inhibitors

Inter Partes Review No.: IPR2016-01566

**Petition for *Inter Partes* Review of U.S. Patent No. 9,173,859 Under
35 U.S.C. §§ 311-319 and 37 C.F.R. §§ 42.1-.80, 42.100-.123**

Mail Stop "PATENT BOARD"
Patent Trial and Appeal Board
U.S. Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

TABLE OF CONTENTS

	<u>Page</u>
I. INTRODUCTION	3
II. OVERVIEW	3
III. STANDING (37 C.F.R. § 42.104(a); PROCEDURAL STATEMENTS)	4
IV. MANDATORY NOTICES (37 C.F.R. § 42.8(a)(1)).....	5
A. Each Real Party-In-Interest (37 C.F.R. § 42.8(b)(1))	5
B. Notice of Related Matters (37 C.F.R. § 42.8(b)(2)).....	5
1. Judicial Matters	5
2. Administrative Matters	5
C. Designation of Lead and Back-Up Counsel and Service (37 C.F.R. §§ 42.8(b)(3), 42.8(b)(4), 42.10(a), and 42.10(b)):	6
V. STATEMENT OF THE PRECISE RELIEF REQUESTED AND THE REASONS THEREFORE (37 C.F.R. § 42.22(a))	6
VI. THE '859 PATENT	6
A. CLAIM CONSTRUCTION	9
VII. EXPERT DECLARATION OF MAYER B. DAVIDSON, M.D.....	9
VIII. PERSON OF SKILL IN THE ART (“POSA”).....	10
IX. IDENTIFICATION OF CHALLENGE (37 C.F.R. § 42.104(b)).....	12
A. The Scope and Content of the Prior Art.....	12
1. Metformin	13
2. DPP-IV Inhibitors	14
3. The Benefits of Combining DPP-IV Inhibitors With Metformin Were Well-Known.....	16

Petition for Inter Partes Review
of U.S. Patent No. 9,173,859

B. Ground 1: Claims 1–22 Are Unpatentable Under 35 U.S.C. § 103(a) over the '510 Publication in view of the Glucophage Label.....18

1. The '510 Publication (Ex. 1003).....18

2. Glucophage Label (Ex. 1004).....19

3. Independent Claims 1, 13, and 16–18.....20

4. Dependent Claims 2–4.....26

5. Dependent Claims 5, 6, 19, 21, 22.....27

6. Dependent Claims 7–12.....28

7. Independent Claim 14 and Dependent Claims 15 and 20.....29

C. Ground 2: Claims 14 and 20 Are Unpatentable Under 35 U.S.C. § 102(b) over the '510 Publication.....30

1. '510 Publication (Ex. 1003).....30

2. Claims 14 and 20.....30

D. Ground 3: Claims 1–22 are Unpatentable Under 35 U.S.C. § 103(a) over the '510 Publication in light of Ahrén, Hughes, and/or Brazg31

1. '510 Publication (Ex. 1003).....31

2. Ahrén (Ex. 1005).....31

3. Hughes (Ex. 1006)34

4. Brazg (Ex. 1007)34

5. Independent Claims 1, 13, and 16–18.....36

6. Dependent Claims 2–4.....40

7. Dependent Claims 5, 6, 19, 21, and 22.....41

8. Dependent Claims 7–12.....42

Petition for Inter Partes Review
of U.S. Patent No. 9,173,859

9. Independent Claim 14 and Dependent Claims 15 and 20.....42

E. Objective Indicia of Nonobviousness43

X. CONCLUSION.....45

TABLE OF AUTHORITIES

	Page(s)
CASES	
<i>Boehringer Ingelheim Pharmaceuticals Inc., et al. v. HEC Pharm Group, et al.</i> , Civ. Action No. 3:15-cv-05982-PGS-TJB (D.N.J.)	5
<i>Cuozzo Speed Techs., LLC v. Lee</i> , 136 S. Ct. 2131 (2016).....	9
<i>Daiichi Sankyo, Ltd. v. Apotex, Inc.</i> , 501 F.3d 1254 (Fed. Cir. 2007)	11
<i>In the Matter of Mahurkar Double Lumen Hemodialysis Catheter Patent Litig.</i> , 831 F. Supp. 1354 (N.D. Ill. 1993), <i>aff'd sub nom.</i> , <i>In re Mahurkar Double Lumen Hemodialysis Catheter Patent Litig.</i> , 71 F.3d 1573 (Fed. Cir. 1995).....	11
<i>KSR Int'l Co. v. Teleflex Inc.</i> , 550 U.S. 398 (2007).....	4, 10
<i>Standard Oil Co. v. Am. Cyanamid Co.</i> , 774 F.2d 448 (Fed. Cir. 1985)	10
STATUTES	
35 U.S.C. §§ 311-319.....	3
OTHER AUTHORITIES	
37 C.F.R. § 42	3
37 C.F.R. § 42(a)(1).....	5
37 C.F.R. § 42.6(d)	12
37 C.F.R. § 42.8(b)(1).....	5
37 C.F.R. § 42.8(b)(2).....	5
37 C.F.R. § 42.8(b)(3).....	6

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.